Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Sales (2016 - 2025)

Historic Return on Sales for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 0.13%.

  • Myriad Genetics' Return on Sales fell 300.0% to 0.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 0.15% for FY2024, which is 2000.0% up from last year.
  • As of Q3 2025, Myriad Genetics' Return on Sales stood at 0.13%, which was down 300.0% from 1.55% recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Return on Sales peaked at 0.15% during Q3 2021, and registered a low of 1.55% during Q2 2025.
  • Over the past 5 years, Myriad Genetics' median Return on Sales value was 0.16% (recorded in 2023), while the average stood at 0.24%.
  • In the last 5 years, Myriad Genetics' Return on Sales soared by 5700bps in 2021 and then crashed by -13800bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Return on Sales stood at 0.05% in 2021, then crashed by -403bps to 0.24% in 2022, then skyrocketed by 33bps to 0.16% in 2023, then fell by -27bps to 0.2% in 2024, then surged by 34bps to 0.13% in 2025.
  • Its Return on Sales stands at 0.13% for Q3 2025, versus 1.55% for Q2 2025 and 0.0% for Q1 2025.